Oncoclínicas has completed the sale of its Saudi oncology venture for US$6.5 million, marking a strategic retreat from the Middle East market.
The Brazilian cancer-care provider received the proceeds in cash upfront from its Saudi partners, finalizing the exit from the joint operation.
The transaction underscores the company’s ongoing push to reduce leverage and streamline its portfolio.
By divesting non-core international assets, Oncoclínicas aims to strengthen its balance sheet and focus capital on its primary operations in Brazil.
The move aligns with a broader trend among Latin American healthcare providers to prioritize domestic growth and financial stability amid global economic uncertainty.
This divestment follows a period of strategic reassessment for Oncoclínicas, which has been under scrutiny for its turnaround progress.